Skip to content

Dj Nutt

3 papers in the library · 53 citations · publishing 2013-2026

Papers

Sort Most recent Most cited

Psilocybin for psychiatric disorders: History, clinical trials, neuroimaging, and regulations

Psychiatry and Clinical Neurosciences February 26, 2026 Kengo Yonezawa, M. Hirata, Hiroaki Takano et al. 1 citation

Psilocybin, a classic psychedelic compound, has garnered renewed interest as a potential treatment for various psychiatric disorders. This review provides a comprehensive overview of psilocybin's history, recent clinical evidence, ongoing clinical trials, neuroimaging findings, and regulations. Historically used in spiritual and healing rituals, psilocybin was in the early 1970s subjected to...

Improved colour blindness symptoms associated with recreational psychedelic use: Results from the Global Drug Survey 2017

Drug Science Policy and Law 2020 Jec Anthony, Adam Winstock, Ja Ferris et al. 9 citations

It is well documented that psychedelic drugs can have a profound effect on colour perception. After previous research involving psychedelic drug ingestion, several participants had written to the authors describing how symptoms of their colour blindness had improved. The Global Drugs Survey runs the world’s largest annual online drug survey. In the Global Drugs Survey 2017, participants...

Psychiatry’s next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders

Journal of Psychopharmacology June 19, 2013 Rl Carhart-Harris, Stefan Brugger, Dj Nutt et al. 43 citations

Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the effects of five drugs (cannabis, psilocybin, amphetamine, ketamine and alcohol) in relation to psychiatric symptoms in a two-part subjective analysis. In the first part, mental health professionals...